On October 28, 2025, Protagenic Therapeutics, Inc. filed a complaint seeking to rescind a previous share exchange agreement with Phytanix Bio, Inc. or, alternatively, to obtain damages and compel the delivery of required audited financial statements. This filing indicates significant legal proceedings related to the company's acquisition.